Metformin Plus Megestrol Acetate as a Fertility-sparing Treatment in Patients With Atypical Endometrial Hyperplasia

  • End date
    Feb 28, 2027
  • participants needed
  • sponsor
    Fudan University
Updated on 20 February 2021


To verify whether metformin could improve the effect of progestin as fertility-sparing treatment in patients with atypical endometrial hyperplasia(AEH).


Whether metformin could improve the effect of progestin as fertility-sparing treatment in patients with atypical endometrial hyperplasia(AEH) is still not clear. Our previous finding from subgroup analysis in a phase II randomized controlled trial showed that 39.6% of AEH patients in metformin plus megestrol acetate group achieved complete response, compared with 20.4% in group of megestrol acetate alone. This trial aim to fully testify the effect of metformin in fertility-sparing treatment for AEH patients with adequate sample size.

Condition Disorder of uterus NOS, Endometrial Hyperplasia, Uterine Disorders, atypical endometrial hyperplasia
Treatment Megestrol Acetate, Metformin plus Megestrol acetate
Clinical Study IdentifierNCT04607252
SponsorFudan University
Last Modified on20 February 2021


Yes No Not Sure

Inclusion Criteria

18-45 years old
pathologically diagnosed with AEH for the first time
desire to preserve their fertility
no signs of suspicious myometrial invasion or extrauterine metastasis by enhanced magnetic resonance imaging (MRI), enhanced computed tomography (CT) or transvaginal ultrasonography (TVUS)
no contraindication for metformin, megestrol acetate or pregnancy
no hormone or metformin treatment within 6 months before entering the trial
not pregnant when participating in the trial
willing to follow the trial arrangement after being fully informed of all the risks and inconveniences caused by the trial

Exclusion Criteria

Patients who had one or more of the following conditions
allergy history or contraindications for megestrol acetate or metformin
pregnant when initiating the study
alcoholism, severe infection, severe chronical diseases (dysfunction of heart, liver, lung or kidney)
high risk of thrombosis
recurrent AEH
endometrial cancer
other malignancy history
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note